Aishwarya Sahasrabudhe
Research Subjects
Aishwarya Sahasrabudhe has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Amenech B. Ashango
Hematologics, Inc., Seattle, Washington
21 shared publications - Andy Kaempf
Cancer Data Science Shared Resource OHSU, Knight Cancer Institute Portland Oregon USA
21 shared publications - Anupriya Agarwal
Division of Oncological Sciences, Oregon Health & Science University, United States
21 shared publications - Arpita Gandhi
Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
21 shared publications - Ashley M. Eckel
Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA
21 shared publications - Brandon Hayes-Lattin
OHSU Knight Cancer Institute, Portland, Oregon, United States
21 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eaec0131
mTOR signaling contributes to system-driven rhythmic gene expression in mouse liver
Rhythmic gene expression is essential to the daily organization of biological processes. While cycling transcriptomes are regulated by circadian clocks present in nearly every cell, accumulating evidence indicates that they can also be initiated by rhythmic food-driven systemic signals independently of circadian clocks. The underlying mechanisms remain however largely unknown. Here, we show that signaling through the nutrient-sensing kinase mechanistic target of rapamycin (mTOR) is both necessary and sufficient to mediate food-driven hepatic rhythmic gene expression, rhythmic regulation of the liver metabolome, and endoplasmic reticulum stress response. Acute inhibition of mTOR before the active phase desynchronizes the phase of mTOR-driven rhythmic genes without affecting clock-controlled rhythmic genes, indicating that alignment of rhythmic mTOR activity to the circadian cycle is critical for overt cycling transcriptomes. These findings may explain how misalignment between clock and systemic signals contributes to disease and underscore the use of mTOR inhibitors for resynchronizing system-driven rhythms and alleviating circadian rhythm disorders.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eaec0131
Open AccessmTOR signaling contributes to system-driven rhythmic gene expression in mouse liver
Rhythmic gene expression is essential to the daily organization of biological processes. While cycling transcriptomes are regulated by circadian clocks present in nearly every cell, accumulating evidence indicates that they can also be initiated by rhythmic food-driven systemic signals independently of circadian clocks. The underlying mechanisms remain however largely unknown. Here, we show that signaling through the nutrient-sensing kinase mechanistic target of rapamycin (mTOR) is both necessary and sufficient to mediate food-driven hepatic rhythmic gene expression, rhythmic regulation of the liver metabolome, and endoplasmic reticulum stress response. Acute inhibition of mTOR before the active phase desynchronizes the phase of mTOR-driven rhythmic genes without affecting clock-controlled rhythmic genes, indicating that alignment of rhythmic mTOR activity to the circadian cycle is critical for overt cycling transcriptomes. These findings may explain how misalignment between clock and systemic signals contributes to disease and underscore the use of mTOR inhibitors for resynchronizing system-driven rhythms and alleviating circadian rhythm disorders.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival based on monocytic differentiation status censored at HCT for patients within specific mutation subgroups including (A) combined RAS pathway mutations (N/KRAS and PTPN11), and isolated mutations in (B) FLT3-ITD, (C) NRAS, (D) KRAS, (E) PTPN11, and (F) TP53. Patients with isolated mutations/mutation groups were wild-type for all other genes tested (NPM1, IDH1/2, N/KRAS, FLT3-ITD, and TP53) except for the gene of interest. Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival based on monocytic differentiation status censored at HCT for patients within specific mutation subgroups including (A) combined RAS pathway mutations (N/KRAS and PTPN11), and isolated mutations in (B) FLT3-ITD, (C) NRAS, (D) KRAS, (E) PTPN11, and (F) TP53. Patients with isolated mutations/mutation groups were wild-type for all other genes tested (NPM1, IDH1/2, N/KRAS, FLT3-ITD, and TP53) except for the gene of interest. Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival in patients classified as monocytic vs. non-monocytic in (A) patients classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53), (B) with mutated IDH1/2 and wild-type for N/KRAS, PTPN11, FLT3-ITD, and TP53, and (C) wild-type for NPM1, FLT3-ITD, IDH1/2, K/NRAS, PTPN11, and TP53. Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival in patients classified as monocytic vs. non-monocytic in (A) patients classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53), (B) with mutated IDH1/2 and wild-type for N/KRAS, PTPN11, FLT3-ITD, and TP53, and (C) wild-type for NPM1, FLT3-ITD, IDH1/2, K/NRAS, PTPN11, and TP53. Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 9 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overview of immunophenotypic expression profiling. (A) Flow cytometry was performed on diagnostic bone marrow specimens and fluorescence measurements, forward light scatter (FSC) and right-angle light scatter (SSC) characteristics were collected for 200,000 events. Leukemic populations were identified by CD45 v SSC gating, and, in a small subset of cases with markedly hypogranular myeloids, by CD34 gate (these cases all contained an entirely CD34 positive blast population). Final gating for every case was reviewed by a pathologist. (B) For cells identified in the leukemia gate, the mean intensity for each parameter (represented by a black dot) was computed.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 9 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overview of immunophenotypic expression profiling. (A) Flow cytometry was performed on diagnostic bone marrow specimens and fluorescence measurements, forward light scatter (FSC) and right-angle light scatter (SSC) characteristics were collected for 200,000 events. Leukemic populations were identified by CD45 v SSC gating, and, in a small subset of cases with markedly hypogranular myeloids, by CD34 gate (these cases all contained an entirely CD34 positive blast population). Final gating for every case was reviewed by a pathologist. (B) For cells identified in the leukemia gate, the mean intensity for each parameter (represented by a black dot) was computed.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental FIgure 5 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival within the US cohort (n = 279) based on the presence of signaling pathway mutations including (A) NRAS, (B) KRAS, (C) PTPN11, (D) BRAF, (E) NF1, and (F) WT1. Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental FIgure 5 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival within the US cohort (n = 279) based on the presence of signaling pathway mutations including (A) NRAS, (B) KRAS, (C) PTPN11, (D) BRAF, (E) NF1, and (F) WT1. Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Patient and disease characteristics for Beat AML RNAseq cohort (N = 228)
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Patient and disease characteristics for Beat AML RNAseq cohort (N = 228)
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival based on (A) NPM1 mutation status, (B) FLT3-ITD mutation status within NPM1 mutated cases only, (C) IDH1 mutation status, and (D) IDH2 mutation status. Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival based on (A) NPM1 mutation status, (B) FLT3-ITD mutation status within NPM1 mutated cases only, (C) IDH1 mutation status, and (D) IDH2 mutation status. Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Surface expression of CD14, CD64, and CD11b in cases by genetic mutation compared to a wild-type reference cohort within the subset of patients with centralized quantitative MFC performed (n = 144). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. ref: reference.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Surface expression of CD14, CD64, and CD11b in cases by genetic mutation compared to a wild-type reference cohort within the subset of patients with centralized quantitative MFC performed (n = 144). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. ref: reference.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
RNA expression of alternative anti-apoptotic proteins based on RNA-seq defined cell differentiation state. Samples from the top quartile of each state are displayed below.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
RNA expression of alternative anti-apoptotic proteins based on RNA-seq defined cell differentiation state. Samples from the top quartile of each state are displayed below.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival in the subgroup of patients not receiving allogeneic cell transplantation (HCT) based on (A) monocytic vs. non-monocytic differentiation, (B) monocytic differentiation and NPM1 mutation status, (C) in the subgroup of patients with RAS pathway and FLT3-ITD mutations (K/NRAS, PTPN11, FLT3-ITD) and wild-type IDH1/2, NPM1, and TP53; (D) within the patient subgroup classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53). Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival in the subgroup of patients not receiving allogeneic cell transplantation (HCT) based on (A) monocytic vs. non-monocytic differentiation, (B) monocytic differentiation and NPM1 mutation status, (C) in the subgroup of patients with RAS pathway and FLT3-ITD mutations (K/NRAS, PTPN11, FLT3-ITD) and wild-type IDH1/2, NPM1, and TP53; (D) within the patient subgroup classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53). Reported p-values utilized the cox model Wald test.